Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Myeloma risk stratification is… complicated in my experience as a MM survivor. But I have to say that risk is everything in the diagnosis and treatment of multiple myeloma. Importantly, the post outlines the risk of a newly diagnosed myeloma patient more specifically than
Unfortunately, conventional oncology prescribes one basic standard-of-care for all newly diagnosed multiple myeloma patients who are transplant eligible.
Risk stratification in the context of multiple myeloma refers to the process of categorizing patients with this type of cancer into different risk groups based on various clinical and biological factors. The goal of risk stratification is to help healthcare providers make more informed decisions about treatment plans and to predict the likely course of the disease for a specific individual.
In multiple myeloma, risk factors can include:
Once these factors are considered, patients may be categorized into different risk groups, which may include:
The specific criteria and methods used for risk stratification can vary depending on the guidelines and protocols followed by a particular medical institution or oncology team. At least, in theory. I say “in theory” I’ve never heard of an oncologist explaining to a MM patient why they are prescribing a given therapy.
In fairness to oncology, it’s important to note that risk stratification is a dynamic process and may be reassessed over time, especially if a patient’s condition changes or if new information becomes available.
Having said the above, I know of many young MM patients (young being under the age of 60) who are fit and who have no co-morbidities but who are prescribed the same standard-of-care therapy plan that most everyone else it.
Ultimately, the goal of risk stratification is to tailor treatment plans to the individual patient’s needs in order to achieve the best possible outcome.
I guess what I’m saying here is that your oncologist should explain to you your risks. Why he/she is prescribing more therapy and for how long. And if you are experiencing side effects, why your oncologist isn’t taking this into account.
I am a myeloma survivor. I was prescribed lots of chemotherapy with no explanation of what, why, when, etc. I am in complete remission because of a quack cancer therapy. Not because of FDA approved, safe and effective MM therapy.
Have you been diagnosed with multiple myeloma? What stage? Any symptoms? Let me know-
“Overall, for patients at standard risk, Callander, a professor in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health in Madison, suggested
the triplet regimen VRd, consisting of the proteasome inhibitor bortezomib (Velcade), the immunomodulatory agent lenalidomide (Revlimid), and the corticosteroid dexamethasone.
This is followed by autologous stem cell transplant (ASCT) and maintenance with lenalidomide until progression, followed by treatment with daratumumab (Darzalex).2
In general, for patients at high risk, defined as
Callander recommended the 4-drug induction, which is VRd plus daratumumab…
“These guidelines proposed by R-ISS were issued in Europe last year and these are in our guidelines that just came out on September 18, 2023,” Callander said. “What we are trying to do is further stratify people,” Callander continued.2,3 Callander noted that in the updated guidelines,
have been highlighted and emphasized as risk factors to consider when treating patients with multiple myeloma.